WebMethods: The observational Global aHUS Registry ( NCT01522183 ), initiated in April 2012, collects demographics, disease history, treatment, and outcomes data for patients with aHUS, regardless of treatment approach. Web29 May 2024 · In this analysis, patients from the Global aHUS Registry (NCT01522183) were included if they were diagnosed with MHT and were followed ≥90 days after initial aHUS symptom presentation or diagnosis date; patients were excluded if they withdrew from the registry or discontinued treatment with eculizumab due to a diagnosis other than aHUS.
The global aHUS registry: methodology and initial patient ...
Web3 Apr 2024 · Background Atypical Hemolytic Uremic Syndrome (aHUS) is an ultra-rare disease. Therefore, studies involving large samples are scarce, making registries powerful tools to evaluate cases. Web26 Jan 2024 · Materials and methods: In this analysis, patients from the Global aHUS Registry (NCT01522183) were included if they were diagnosed with MHT and were followed ≥90 days after initial aHUS symptom presentation or diagnosis date. Demographics and clinical characteristics were evaluated . Table. ... frog grove lane wood street village
Clinical characteristics and outcomes of a patient population with ...
Web1 Aug 2024 · The Global aHUS Registry is an ongoing, observational, noninterventional, multicenter, multinational study (NCT01522183) designed to retrospectively and prospectively collect information on the long-term outcomes and health status of patients with aHUS, as well as the long-term safety and effectiveness of eculizumab in this … WebIn this study, we characterize patients (pts) with triggering/associated events occurring prior/up to aHUS onset from the Global aHUS Registry (NCT01522183). Methods. All pts with triggering/associated events prior/up to aHUS onset and enrolled in the Registry from 2011 to July 2024 were included. Pts with an alternative clinical diagnosis ... WebAbstract. Background: Atypical hemolytic uremic syndrome (aHUS) is a rare disease in which uncontrolled terminal complement activation leads to systemic thrombotic … frog growth and development